Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Epiminder Wins FDA Clearance to Extend Minder Use to Adolescents

EPI: $0.265 +0.00% · MC: $61M

The FDA cleared Epiminder’s Minder system for patients aged 12 and older, expanding eligibility from adults aged 18 and above to include adolescents with drug-resistant epilepsy. Separately, DETECT enrolment reached 100 patients ahead of the company’s November target and is now past halfway towards its planned enrolment of up to 210; Epiminder says it remains on track to complete enrolment by the end of the first half of 2027. The company reported cash of approximately $65 million at September’s end, with no borrowings, and said this is expected to fund activities well into 2028.

Source announcements: 2026-10-30 09:46 to 2026-10-30 14:15 Sydney time
Story updated 2026-10-30 14:20 Sydney time
SourcesFY27 YTD operational update and AGM materialsMinder System Cleared for Patients 12 -75 Years of AgeResults of Annual General Meeting
Comments